An interdisciplinary consortium was formed between several Russian organizations to develop radiopharmaceutical approaches for effective diagnostics and therapy of prostate cancer. The consortium aims to improve production technologies for Tc-99m and Re-188 generators, develop new quality assurance procedures, and produce radiopharmaceuticals that specifically target prostate cancer receptors. They also plan to develop an educational program to train specialists in technetium applications for prostate radiodiagnostics. The new radiopharmaceuticals and trained specialists will help improve prostate cancer management in Russia.

1. Interdisciplinary
consortium collaboration
for the development of
radiopharmaceutical
approach for effective
diagnostics and therapy of
prostate cancer in Russia
K. German1,2, O. Vlasova3, V. Petriev4, V. Skvortsov4, G.
Kodina5, A. Maruk5, N. Airapetova6, N. Epshtein6, N. Nerozin3,
A. Safonov1,2, V. Lebedev1, Ya. Obruchnikova1,2, Yu. Shevko3
1 - A.N. Frumkin Institute of Physical Chemistry and Electrochemistry RAS, Moscow
2 - Medical Institute Reaviz, Moscow branch, Russia
3 - A. I. Leipunsky Institute for Physics and Power Engineering, Obninsk, Russia
4 - Medical Radiological Research Center of Ministry of Health of Russia, Obninsk,
Russia
5 - Burnazyan Federal Medical Biological Center of FMBA, Moscow, Russia
6 - National Research Nuclear University MEPhI, Obninsk, Russia

2. Consortium organigram
Direсtorate
A.N. Frumkin
Institute of Physical
Chemistry and
Electrochemistry RAS,
Moscow
Medical
Institute Reaviz,
Moscow branch,
Russia
Burnazyan Federal
Medical Biological
Center of FMBA,
Moscow, Russia
A. I. Leipunsky Institute for
Physics and Power
Engineering, Obninsk,
Medical Radiological
Research Center of
Ministry of Health of
Russia, Obninsk, Russia
National Research
Nuclear University
MEPhI, Obninsk,
Russia
Russia
Tc-99m for
prostate cancer
diagnostics and
Re-188 for treatment

3. A.N. Frumkin Institute of Physical
Chemistry and Electrochemistry RAS,
Moscow
Technetium chemistry laboratory
• K. German, Project CEO, Head of Tc
laboratory, PhD , Doc., Prof.
• A. Safonov, Deputy head of Tc laboratory, PhD
• Ya. Obruchnikova, PhD
• V. Tregubova, PhD student
• M. Glazkova
Innovation department
• V. Lebedev, General manager for innovations
Laboratory of new physical-chemical problems
• A. Tsivadze, Director of IPCE RAS, Academician
• A. Filyanin, liquid extraction group, PhD
• V. Tarasov, NMR analysis, Professor
Laboratory of substance radiation chemistry
• B. Ershov, Head of laboratory, corr. member
RAS, Professor
• E. Abkhalimov, PhD
• R. Solovov, PhD student
Laboratory of interphase boundaries and
electocatalysis
• V. Andreev, Head of laboratory, Professor
Laboratory of radioactive material analysis
• M. Grigoriev, Head of laboratory, Professor

4. • The main purpose of the Institute is to carry
out fundamental and applied scientific
research in various fields of physical chemistry,
electrochemistry, chemical resistance of
materials, radiochemistry and radiation
chemistry.

5. A. I. Leipunsky Institute for Physics and
Power Engineering, Obninsk, Russia
• O. Vlasova, N. Nerozin, Yu. Shevko, I. Zhuk
• multidisciplinary scientific organization,
conducting complex investigations of physical
and technical problems of nuclear science and
technology.

6. Medical Radiological Research Center
of Ministry of Health of Russia,
Obninsk, Russia
• V. Skvortsov, V. Petriev
• Mission: Development of concepts, regulatory
documents related to radiation safety of a human
and the environment, health security and
reduction of socioeconomic prejudice caused by
radiation.
• The Institute was founded in 1962 to develop and
improve methods of radiation diagnostics and
radiation therapy, prevention and treatment of
radiation injury, the study of the biological and
medical effects of ionizing radiation.

7. National Research Nuclear University
MEPhI, Obninsk, Russia
• N. Airapetova, N. Epshtein
• Development of analytical procedures
for quality control of
radiopharmaceuticals and staff training
• Mission: to generate, disseminate the use and to
preserve scientific knowledge aiming to address
global challenges of the XXI century, as well as to
provide innovative transformations in Russia
accompanying development of the country
competitiveness in the global energy and non-energy
high-tech markets.

8. Burnazyan Federal Medical Biological
Center of FMBA, Moscow, Russia
• G. Kodina, PhD, Department head
• A. Maruk, PhD, Laboratory Head
• Production of Tc-99m (for radiodiagnostics)
and Re-188 (for radiotherapy) isotopes and
preclinical medicine tests
• Fundamental and applied research in the field of radiation
medicine, radiobiology and radiation protection;
• Research in the field of biomedical technologies, radiopharmacy;
• Development of new radiation technologies (including photon
and neutron capture therapy);
• Research in the field of chemical and radiation safety in the use
of technology for special applications.

9. Medical Institute Reaviz,
Moscow branch, Russia
• K. German, Chair of Natural science, Professor
• A. Safonov, docent, PhD
• Ya. Obruchnikova, assistant prof., PhD
• V. Tregubova, PhD student
• Training of medical staff for modern medicine
“The main aim of Reaviz is the training of health care staff, of young people
who should become highly professional physicians in the nearest future. The
most important quality for these professionals should be the integration of the
greatest responsibility and the inner freedom of this profession, of scientific
research and practical achievements.” Rector of Samara Medical Institute
“REAVIZ”, Doctor of Medical Science, professor Nikolay A. Lyssov

10. What we intend to obtain
In the course of this project should be developed
• production technologies of 99mTc generators and high-value
188Re generators with reduced transport index,
• technologies of 188Re concentration, development of
analytical methods for detection of radioactive and
chemical impurities in the 188Re preparation,
• quality assurance of 99mTc and 188Re generator eluates
in accordance with the requirements of potential
radiopharmaceuticals based on them, specifically binds
to the receptor tissue of prostate cancer.

11. What we already have
for radionuclide imaging
• 2-18F-fluoro-2-deoxy-D-glucose (FDG);
• 111In-7E11 antibody (ProstaScint);
• 18F-fluorodihydrotestosterone (18F-FDHT);
• radioacetate analogs;
• radiocholine analogs;
• anti-1-amino-3-18F-fluorocyclobutane-1-carboxylic
acid (anti-[18F]FACBC)
Production of Tc-99m (for radiodiagnostics) and Re-188
(for radiotherapy) isotopes were improved with
optimized generator design aimed to high specific activity
production.

12. • Potential consumer of radiopharmaceuticals
(RPh): medical institutions at various levels,
cancer medical centers, cancer clinics, licensed to
work with sources of ionizing radiation and
equipped with diagnostic equipment, SPECT or
PET.
• Objects of RPh application: patients with the
disease of prostate cancer (about 30 thousand
pers. / year).
• Over the past few years in Russia approximately
40,000 new cases of prostate cancer per year
were recorded, and only for 30% of them
brachytherapy is performed with an efficiency of
75%

13. Effective diagnostics and therapy of
prostate cancer is an important issue
for Russia due to constantly increasing
number of decease cases herein.
Rational development of new radiopharmaceuticals
for the management of advanced and metastatic
prostate cancer requires an improved cooperation
of the organization thus involved. For this reason an
interdisciplinary consortium collaboration for the
development of radiopharmaceutical approach is
established with principle aim to improve the
situation within the 3 coming years.

14. The development of new radiopharmaceuticals
and generators for the management of
advanced prostate cancer will help to improve
the treatment of this disease in Russia.

15. • Special educational interdisciplinary program for
specialist training for technetium application to
prostate radiodiagnostics is elaborated.
• The development of new radiopharmaceuticals
and generators for the management of advanced
prostate cancer will help to improve the treatment
of this disease in Russia.
• Innovative character of this project requires special
attention on staff training.
• New technologies worked out by Igor Zhuk and
Yury Shevko (A.I. Leipunsky Institute for Physics
and Power Engineering, Obninsk, Russian
Federation) are to be used in this project

16. A new approach to
form a competent team of
specialists

17. What makes a good specialist?
Interest Competence
Objectivity Creativity
Self-criticism
Efficiency

18. Many issues written by leading scientists state
that the expert is endowed mainly the
following qualities, namely:
1) has a degree in the subject area;
2) has a positive experience with previous
expertise in the subject area;
3) must work at least 10 years;
4) objective;
5) must constantly improve their knowledge and
so on.

19. Is it true?
In our opinion, these qualities are of a formal
nature and do not meet the full competencies
that have been proposed by the European
community as one of the core competences for
professionals of the twenty-first century.

20. Five basic EU competencies were chosen as the most
necessary for the Expert of the XXI century :
1. Communication in the mother tongue.
2. Communication in foreign languages.
3. Mathematics skills and core competencies
(skills) in science and technology.
4. Information technology competence.
5. The ability to find new information and
produce new knowledge for expert’s
professional area.

21. Ask yourself: “Are you sure that You
have all this basic competencies?”
Or Do You think that the expert and specialist of
technetium application to prostate
radiodiagnostics do not need
this competencies?
Unfortunately, it is not a simple question.
Please, think about quantity of the wrong
diagnosis in different countries

22. Thank you
for the attention !

23. • The PSMA markers are focus selection of the project
due to their ability not only for cancer but also for
methastatic object detection. Draw investigation
indicated that the prostate-specific membrane antigen
(PSMA) based markers could be the key substrate
matter for the solution of the problem. PSMA is highly
expressed in prostate cancer, and small-molecule
radiopharma-ceuticals targeting PSMA helps to rapidly
detect the location and extent of disease. Comparative
study provided with a selected row of substrates
including several MIP derivatives and some others.
Synthetic procedures were optimized for better yields,
purities and prices.

24. Expert assessments in Russia
• Expert assessments are applied with success
in various fields of human activity and find
their reflection in the works of such Russian
scientists as Azgaldov G.G., Beshelev S.D.,
Evlanov L.G., Gurvich F.G., Larichev O.I., Litvak
B.G., Novikov, D. A., Orlov, A.I., Raichman I.P.,
Sidelnikov Y.V., and many other authors
involved in problem of expert assessments.
24

25. Evlanov L.G. thought that the expert
has the following requirements:
1) Competence;
2) Creativity;
3) Respect to the examination;
4) Conformism;
5) Constructive thinking;
6) Teamwork;
7) Self-criticism.
25

26. In the work of Raichman A.P. and Azgldov G.G. the
quality of the expert has the following requirements:
1) Competence;
2) Interest;
3) Efficiency;
4) Objectivity.
The competence of the expert should be applied
to the object quality assessment (professional
competence) and methodology (qualitative
competence).

27. Data about the authors
• Zhuk Igor Aleksandrovich, PHD,
• Shevko Yuri Viktorovich,
e-mail: zz-38@yandex.ru
• (A. I. Leipunsky Institute for Physics and Power
Engineering, Obninsk, Russia)